SCHEDULE: Investment Funds Disclose Passive Stake in ProQR

Multiple Dutch investment entities and their portfolio manager have disclosed passive beneficial ownership stakes in ProQR Therapeutics N.V., with Privium Fund Management B.V. and Patrick Johan Hendrik Krol each holding 5.2%.

Summary

• Stichting Aescap Life Sciences, Privium Fund Management B.V., Stichting Aescap Genetics, Inspirational Visions B.V., and Patrick Johan Hendrik Krol have filed a Schedule 13G for ProQR Therapeutics N.V.
• The filing indicates passive beneficial ownership of ProQR Therapeutics N.V. ordinary shares, nominal value EUR0.04 per share.
• As of December 11, 2025, Stichting Aescap Life Sciences beneficially owned 4,156,878 shares, representing 3.9% of the class.
• Privium Fund Management B.V. beneficially owned 5,467,149 shares, representing 5.2% of the class.
• Stichting Aescap Genetics beneficially owned 1,310,271 shares, representing 1.2% of the class.
• Inspirational Visions B.V. beneficially owned 35,411 shares, representing 0.1% of the class.
• Patrick Johan Hendrik Krol beneficially owned 5,528,862 shares, representing 5.2% of the class, which includes shares held by Aescap Life Sciences, Aescap Genetics, and Inspirational Visions, plus his direct holdings.
• The ownership percentages are based on 105,345,192 ordinary shares outstanding as of September 30, 2025, as disclosed in ProQR's Form 6-K filed on November 6, 2025.
• The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: This filing is a routine disclosure of passive beneficial ownership and does not contain information that would significantly alter sentiment regarding the company's operational or financial performance.

Future Outlook

This filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance from the issuer or the reporting persons regarding the issuer's future performance or strategy.

Industry Context

This filing indicates continued institutional investor interest in ProQR Therapeutics N.V., a biotechnology company. The disclosure of a significant passive stake by multiple related investment entities suggests a long-term, non-activist investment approach.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant passive institutional holders and their collective influence, particularly with Privium Fund Management B.V. and Patrick Johan Hendrik Krol each holding 5.2%.

Key Dates

Keywords

ProQR Therapeutics, Schedule 13G, Beneficial Ownership, Institutional Investor, Privium Fund Management, Stichting Aescap, Patrick Krol, Biotechnology, Netherlands, N71542109